- The coronavirus disease 2019 (COVID-19) pandemic has caused more deaths due to both COVID-19 and other clinical conditions such as cardiovascular disease. The relationship between atrial fibrillation (AF) and COVID-19 infection is complex.1 Indeed, AF has found to be associated with a significantly increased risk of short-term mortality in patients infected with severe acute respiratory syndrome coronavirus 2.2 Furthermore, patients with COVID-19 per se have an increased risk of developing AF.3 The aim of the present study was to investigate the trend of AF-related mortality in the United States before and during the COVID-19 pandemic.
- Children and young adults with preexisting cardiovascular disease (CVD) may be disproportionately affected by the collateral health consequences of the coronavirus disease 2019 (COVID-19) pandemic. In addition to a higher risk of morbidity and mortality from COVID-19,1 young persons with CVD may be more susceptible to alterations in physical activity (PA) and poor health outcomes2 owing to the unprecedented loss of structured school days, reduced sports participation, increased screen time, and social isolation.
- First reports from the initial epicenter of the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China included case series of rapid clinical deterioration of seemingly healthy individuals.1,2 Based on a cohort of 138 Chinese patients, 16.7% of patients with COVID-19 suffered from unspecified arrhythmias despite cardiac biomarkers being within normal range. In patients admitted to the intensive care unit (ICU), arrhythmias was reported in 44.4% of the patients. But how diagnosis of arrhythmias were made was not clearly specified.
- A 49-year-old healthy woman presented with exertional shortness of breath and palpitations of 3 months’ duration. Baseline electrocardiogram (ECG) was normal. Figure 1 shows selected tracings recorded during treadmill stress testing. Transthoracic echocardiogram showed no structural abnormalities. Cardiac positron emission tomogram showed normal myocardial perfusion and no abnormal fluorodeoxyglucose uptake. Antibody titers for Lyme disease were undetectable. Figure 2 shows selected tracings from an invasive electrophysiological (EP) study.
- The COVID-19 pandemic has impacted patients’ willingness and ability to engage with healthcare systems. To adapt to the “new normal,” healthcare providers have implemented processes that add more complexity to the process of making an appointment with our physician and entering the office to receive care. We can all agree that the purpose is to keep people safe and reduce the potential for exposure to COVID-19. However, the messaging about COVID-19 and the risk to people with heart disease has created fear and uncertainty for patients.
- Coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), involves other body organs besides the lungs. In recovered patients, post-acute sequelae of COVID-19 may include dysautonomia, in which changes in functioning of ≥1 components of the autonomic nervous system (ANS) adversely affect health. This viewpoint focuses on the dysautonomia postural tachycardia syndrome (POTS).
- Since emerging from Wuhan, China, in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), has infected >3.2 million individuals worldwide and ∼1 million in the United States (as of April 29, 2020).1,2 Despite the institution of measures designed to “flatten the curve,” COVID-19 has claimed the lives of >225,000 individuals worldwide and >60,000 individuals in the United States alone (as of April 29, 2020).2 Of note, mortality estimates in some of the hardest hit regions have already or may need to be revised to account for a spike in sudden deaths occurring at home.
- The case for chloroquine and hydroxychloroquine, as treatment of the coronavirus disease 2019 (COVID-19) pandemic, has been voiced not only in medical journals1 but also in the popular press.2 Not only is the efficacy of these antimalarial and anti-inflammatory compounds as antiviral drugs uncertain, but there is also an ongoing debate about their safety.3 In particular, the magnitude of the proarrhythmic potential of these drugs, specifically related to their QT prolongation effects, is questioned: On the one hand, the fact that chloroquine and hydroxychloroquine block the rapid component of the delay rectifier potassium current (Ikr) potassium channel at the myocyte level, therefore causing QT prolongation, is well documented.